Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment

Background  Several clinical trials showed that erlotinib was effective after the failure of gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the feasibility of erlotinib treatment after the failure of gefitinib based on the data from our hospital.

Methods  The clinical data of 20 patients with advanced NSCLC who were admitted to Shanghai Chest Hospital from August 2007 to December 2008 were retrospectively analyzed. All of the patients were given erlotinib treatment after the failure of gefitinib. Survival analysis was made by Kaplan-Meier method. The Cox regression model was performed to analyze the relationship between the influential factors and the erlotinib progression-free survival (PFS).

Results  Five patients had a partial response (PR), nine patients had stable disease (SD) and six patients had progressive disease (PD) with gefitinib treatment. The median PFS was 277 days (95% CI 0–566). No patient had a PR, seven had SD and fourteen PD with the erlotinib therapy. The median PFS was 31 days (95% CI 9.1–52.9). The response rate (RR) was 0, and the disease control rate (DCR) was 35% (7/20). Cox regression analysis demonstrated that sex (P=0.96), age (P=0.89), smoking history (P=0.78), performance status (PS) (P=0.98), gefitinib efficacy (P=0.90) and whether chemotherapy was applied between using the two drugs (P=0.45) had no significant correlation with erlotinib PFS. Fifteen patients had epidermal growth factor receptor (EGFR) mutation status determined. There were five cases got SD with the erlotinib treatment in ten mutation negative (wild-type) patients. No SD was recorded in the five mutation positive patients.

Conclusions  The efficacy of erlotinib treatment after gefitinib failure was limited. However, the patients who are EGFR mutation negative can probably benefit from erlotinib treatment after gefitinib failure.

     

How to determine the dosage of oral progesterone among patients with menstrual disorders?

Background  Few studies have given suggestions on appropriate individual progesterone dosage in patients with progesterone deficiency. This study was designed to provide a reference for the clinical use of oral progesterone by exploring the relationship among Body Mass Index (BMI), dosage of progesterone, and serum progesterone concentration. Many gynecology and obstetrics doctors are unfamiliar with progesterone treatment. Our study is intended to help determine the dosage of oral progesterone.

Methods  This was a block randomized, open-label, prospective clinical trial. Eighty women undergoing cessation of menses were recruited, given oral progesterone therapy for 10 consecutive days. They were randomly assigned to four groups (four different doses of progesterone, n=20): group A 100 mg/d, group B 200 mg/d, group C 300 mg/d, and group D 400 mg/d.

Results  Seventy-four patients (92.5%, 74/80) completed the study. It was observed that administration of progesterone significantly increased serum progesterone concentration in the four groups (all P <0.001). And there is a positive correlation between the increase and dosage (r_p=0.613, P <0.001). A further linear regression analysis found the major regression equation: when 18.5 kg/m² ≤BMI <24 kg/m², Y=8.4820×10^0.003X (R²=0.425, P <0.001); Y was the increase of serum progesterone concentration in nmol/L, and X was the dosage of oral progesterone in mg/d.

Conclusions  Serum progesterone levels went up linearly as the dosage increased. The higher the patient’s BMI, the higher dosage would be needed to achieve the same serum progesterone concentration. The appropriate dosage of oral progesterone for different patients can be roughly calculated in light of the results of this study.

     

Characteristic gene expression profiles in the progression from normal gastric epithelial cells to moderate gastric epithelial dysplasia and to gastric cancer

Background  Gastric cancer ranks high among the most common causes of cancer-related death worldwide. This study was designed to explore key genes involved in the progression of normal gastric epithelial cells to moderate gastric epithelial dysplasia (mGED) and to gastric cancer.

Methods  Twelve pairs of mGED tissues, gastric cancer tissues, and normal gastric tissues were collected by gastroscopy. Total RNA was then extracted and purified. After the addition of fluorescent tags, hybridization was carried out on a Gene chip microarray slide. Significance analysis of microarrays was performed to determine significant differences in gene expression between the different tissue types.

Results  Microarray data analysis revealed totally 34 genes that were expressed differently: 18 highly expressed (fold change >2; P <0.01) and 16 down-regulated (fold change >2; P <0.01). Of the 34 genes, 24 belonged to several different functional categories such as structural molecule activity, extracellular regions, structural formation, cell death, biological adhesion, developmental processes, locomotion, and biological regulation that were associated with cancer. The remaining 10 genes were not involved in cancer research. Of these genes, the expression levels of Matrix metalloproteinase-12 (MMP12), Caspase-associated recruitment domain 14 (CARD14), and Chitinase 3-like 1 (CHI3L1) were confirmed by semi-quantitative RT-PCR. A two-way clustering algorithm divided the 36 samples into three categories and the overall correct classification efficiency was 80.6% (29/36). Almost all of these genes (31/34) showed constant changes in the process of normal gastric epithelial cells to mGED to gastric cancer.

Conclusions  The results of this study provided global gene expression profiles during the development and progression from normal gastric epithelial cells to mGED to gastric cancer. These data may provide new insights into the molecular pathology of gastric cancer which may be useful for the detection, diagnosis, and treatment.

     

Clinical study of distribution and drug resistance of pathogens in patients with severe acute pancreatitis

Background  Previous researches about necrotic pancreatic tissue infections are numerous, but the study on systemic infection related to the severe acute pancreatitis (SAP) treatment period is limited. This study aimed to investigate the distribution and drug resistance of pathogenic bacteria in patients who had hepatobiliary surgery for SAP during the past three years. 

Methods  A retrospective study was conducted on the distribution, category and drug resistance of pathogenic bacteria in patients who had hepatobiliary surgery for SAP from 2008 to 2011. 

Results  A total of 594 pathogenic bacteria samples were isolated. Among them 418 isolates (70.4%) were Gram bacteria negative, 142 isolates (23.9%) were Gram bacteria positive, and 34 isolates (5.7%) were found fungi. The most common Gram negative bacteria were Escherichia coli (19.8%), and the dominant Gram positive pathogenic bacteria were Enterococcus faecium. The distribution of SAP-related infectious pathogens was mainly in peritoneal drainage fluid, sputum, bile, and wound secretions. Almost all the Gram negative pathogenic bacteria were sensitive to carbapenum. Extended-spectrum β-lactamases (ESBLs) producing strains were more resistant to penicillins and cephalosprins than the ESBLs non-producing strains. Staphylococcus was sensitive to vancomycin and linezolid. The drug resistance of meticillin-resistant staphylococcus (MRS) to commonly used antibiotics was higher than meticillin-sensitive streptococcus (MSS). Enterococcus sp. exhibited lower drug-resistance rates to vancomycin and linezolid.

Conclusions  Gram negative bacteria were the dominant SAP-related infection after hepatobiliary surgery. A high number of fungal infections were reported. Drug resistant rates were high. Rational use of antibiotics according to the site of infection, bacterial species and drug sensitivity, correctly executing the course of treatment and enhancing hand washing will contribute to therapy and prevention of SAP-related infection and decrease its mortality.

     

Hypoadiponectinemia predicts impaired endothelium-independent vasodilation in newly diagnosed type 2 diabetic patients: an 8-year prospective study

Background  Adiponectin is an adipokine with insulin-sensitising and anti-atherogenic properties. The aim of this study was to investigate whether low adiponectin levels predict the impairment of endothelial function in newly diagnosed type 2 diabetic patients in an 8-year prospective study.

Methods  In the prospective study, we enrolled 133 newly diagnosed type 2 diabetic patients without subclinical atherosclerosis and gave them intensive therapy; the mean treatment period was 8 years. Intensive treatment was a stepwise implementation of behavior modification and pharmacological therapy targeting hyperglycaemia, hypertension, dyslipidaemia and obesity. We measured baseline circulating adiponectin with an enzyme-linked immunosorbent assay, endothelium-dependent and -independent vasodilation by high-resolution vascular ultrasound. At year 8, 102 patients were reexamined for endothelium-dependent and -independent vasodilation.

Results  Sex-adjusted adiponectin level was positively correlated with endothelium-independent vasodilation both at baseline (r=0.150, P=0.043) and at year 8 (r=0.339, P=0.001), whereas no association was found between adiponectin and endothelium-dependent vasodilation. In a stepwise multivariate linear regression model, adiponectin was an independent predictor for impaired endothelium-independent vasodilation at year 8 (P=0.001).

Conclusions  Plasma adiponectin concentration was associated with endothelium-independent vasodilation and hypoadiponectinemia predicted the impairment of endothelium-independent vasodilation in newly diagnosed type 2 diabetic patients under multifactorial intervention. These data support the causative link of impairment of endothelium-independent vasodilation with hypoadiponectinemia.

 

     

Discovery and identification of serum biomarkers of Wilms’ tumor in mice using proteomics technology

Background  Wilms’ tumor (nephroblastoma) is a cancer of the kidneys that occurs typically in children and rarely in adults. Early diagnosis is very important for the treatment and prognosis of the disease. The aim of our study was to discover and identify potential non-invasive and convenient biomarkers for the diagnosis of Wilms’ tumor.

Methods  Nude mice were used to construct a Wilms’ tumor model by injecting nephroblastoma cells into their bilateral abdomen. We collected 94 serum samples from mice consisting of 45 samples with Wilms’ tumor and 49 controls. The serum proteomic profiles of the samples were analyzed via surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. The candidate biomarkers were purified by high-performance liquid chromatography, identified by liquid chromatography–mass spectrometry, and validated using ProteinChip immunoassays.

Results  We finally retrieved two differential proteins (m/z 4509.2; 6207.9), which were identified as apolipoprotein A-II and polyubiquitin, respectively. The expression of apolipoprotein A-II was higher in the Wilms’ tumor group than in the control group (P <0.01). By contrast, the expression of polyubiquitin was lower in the Wilms’ tumor group than in the control group.

Conclusion  Apolipoprotein A-II and polyubiquitin may be used as potential biomarkers for nephroblastoma in children, and the analysis of apolipoprotein A-II may help diagnose and treat Wilms’ tumor.

     

Tumor-infiltrating regulatory T cells are positively correlated with angiogenic status in renal cell carcinoma

Background  Immune cells within a tumor microenvironment have shown modulatory effects on tumor angiogenic activity. Renal cell carcinoma (RCC) is a hypervascular tumor that reportedly increases the frequency of regulatory T cells (Tregs) in tumor tissues. This study investigated the correlation between Tregs infiltration and angiogenic status in RCC.

Methods  Thirty-six patients with RCC were enrolled in the present study, and twenty age-matched healthy donors were included as the control. Tregs were defined as CD4⁺CD25^highCD127^low/– T cells. The frequency of Tregs in peripheral blood and tumor infiltrating lymphocytes (TILs) were determined by flow cytometry. The expression of vascular endothelial growth factor (VEGF) in surgical resection specimens were measured with a commercial enzyme-linked immunosorbent assay (ELISA) kit. Microvessel density (MVD) was calculated on slides stained with CD34 antibody. Spearman’s rank correlation was performed to evaluate the correlation between the frequencies of Tregs in TILs and VEGF values, as well as between frequencies of Tregs and MVD determinations.

Results  Compared to healthy controls, the frequency of peripheral blood Tregs was significantly increased in patients with RCC (P <0.05). The percentage of tumor-infiltrating Tregs was higher than that of peripheral blood Tregs in patients with RCC (P <0.01). In addition, the frequency of tumor-infiltrating Tregs was shown to significantly correlate with the pathological stage (P <0.05) and nuclear grade (P <0.01). Importantly, a significant positive correlation was observed between the frequency of tumor-infiltrating Tregs and VEGF protein expression (r=0.51, P <0.05), as well as between frequencies of Tregs and MVD score (r=0.39, P <0.05).

Conclusions  These observations suggest that the high pro-angiogenic status of RCC may be associated with the accumulation of Tregs in the local microenvironment. Angiogenesis networks may be connected with immune tolerance units and cooperate with each other to facilitate tumor growth and progression.

     

Clinical evaluation of remineralization potential of casein phosphopeptide amorphous calcium phosphate nanocomplexes for enamel decalcification in orthodontics

are the focus of intense research. The aim of this study was to evaluate the remineralizing effect of casein phosphopeptide amorphous calcium phosphate (CPP-ACP) nanocomplexes on enamel decalcification in orthodontics.

Methods  Twenty orthodontic patients with decalcified enamel lesions during fixed orthodontic therapy were recruited to this study as test group and twenty orthodontic patients with the similar condition as control group. GC Tooth Mousse, the main component of which is CPP-ACP, was used by each patient of test group every night after tooth-brushing for six months. For control group, each patient was asked to brush teeth with toothpaste containing 1100 parts per million (ppm) of fluoride twice a day. Standardized intraoral images were taken for all patients and the extent of enamel decalcification was evaluated before and after treatment over this study period. Measurements were statistically compared by t test.

Results  After using CPP-ACP for six months, the enamel decalcification index (EDI) of all patients had decreased; the mean EDI before using CPP-ACP was 0.191±0.025 and that after using CPP-ACP was 0.183±0.023, the difference was significant (t=5.169, P <0.01). For control group, the mean EDI before treatment was 0.188±0.037 and that after treatment was 0.187±0.046, the difference was not significant (t=1.711, P >0.05).

Conclusion  CPP-ACP can effectively improve the demineralized enamel lesions during orthodontic treatment, so it has some remineralization potential for enamel decalcification in orthodontics.

     

Impact of diabetes on the prognosis of hip fracture: a cohort study in the Chinese population

Background  Diabetes has been associated with increased risk of fracture and impaired fracture healing. The aim of this study was to examine the influence of diabetes on perioperative complications, length of stay and ambulatory ability recovery in individuals with hip fracture, and to determine whether changes could be made to improve treatment outcome.

Methods  The study included 707 hip fracture patients treated at Beijing Jishuitan Hospital between July 2009 and December 2010. The medical history and perioperative complications were compared between non-diabetic and diabetic groups. Length of stay, days awaiting surgery, and days of hospitalization after surgery were also analyzed. Ambulatory ability was compared at 1-year follow-up using the Chi-square test and Fisher’s exact test. An independent Student’s t-test was used to compare normally distributed continuous data.

Results  Patients with diabetes were more likely than non-diabetic patients to develop cardiac perioperative complications (8.9% vs. 3.0%, P=0.021), urinary tract infections (12.0% vs. 2.8%, P <0.001), and gastrointestinal symptoms (15.0% vs. 6.8%, P=0.003). No difference in perioperative complications was observed between the groups. Days awaiting surgery and length of hospital stay were both longer in the diabetic group ((8.0±5.1) vs. (6.2±3.7) days and (16.5±3.8) vs. (13.3±3.8) days, P <0.001, respectively). Before the occurrence of fracture, patients with diabetes were less likely to be ambulatory outdoors (71.9% vs. 85.9%, P <0.001) and had more restricted walking ability. After at least 1-year follow-up, similar proportions of patients in the non-diabetic and diabetic groups (16.1% and 15.9%, respectively), who were able to ambulate outdoors before the fracture, became housebound till the final follow-up.

Conclusions  Diabetics are at increased risk of specific complications and have a longer time to surgery and longer in-hospital stay, but generally have similar recovery to non-diabetics thereafter.

     

男性冠心病患者血清高敏C反应蛋白及尿酸水平的变化及其临床意义

目的 检测分析男性冠心病(CHD)患者血清高敏C反应蛋白(hs-CRP)和尿酸水平变化及其临床意义.方法 收集2016年1~7月本院心内科男性CHD住院患者158例,其中稳定性心绞痛(SA)55例、不稳定性心绞痛(UA)67例、急性心肌梗死(AMI)36例.收集同时期心内科因胸闷胸痛症状住院,经冠状动脉造影技术排除CHD的男性患者54例作为对照组.采用免疫比浊法检测所有患者血清hs-CRP和尿酸浓度,统计学分析二者水平在男性CHD各组及对照组间的差异.结果 男性CHD患者AMI组、UA组、SA组及对照组血清hs-CRP浓度依次为(44.86±48.30)mg/mL、(8.38±13.26)mg/mL、(0.75±0.74)mg/mL、(0.79±1.27)mg/mL,AMI组水平明显高于UA组、SA组及对照组,且UA组高于SA组和对照组,差异均具有显著统计学意义(P<0.01).男性CHD患者AMI组、UA组、SA组及对照组血清尿酸浓度依次为(345.66±118.82)mg/mL、(403.45±95.86)mg/mL、(343.25±75.09)mg/mL、(339.48±58.28)mg/L,UA组血清尿酸水平明显高于SA组、AMI组和对照组,差异均具有统计学意义(P<0.05).结论 血清hs-CRP和尿酸水平与男性CHD的发生发展关系密切,对于诊断评估男性CHD有一定的价值.     

124例重度阻塞性睡眠呼吸暂停低通气综合征患者肾脏功能评估

目的:比较重度阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者与健康体检者肾功能状况,探讨OS-AHS对肾脏功能是否存在影响。方法:入选重度OSAHS患者124例,均在清晨空腹抽取静脉血检查血肌酐、尿酸、胱抑素C,留取中段晨尿检查尿常规及尿微量白蛋白,同时选择健康体检无打鼾者75例作为对照。结果:①血肌酐及尿酸水平:重度OSAHS组与健康体检组无统计学差异(P>0.05);②血胱抑素C水平:重度OSAHS组与健康体检组存在统计学差异(P<0.01)。③尿微量白蛋白水平:重度OSAHS组与健康体检组存在统计学差异(P<0.05)。结论:重度OSAHS患者虽然在血肌酐、尿酸水平与健康者无统计学差异,但在血肌酐、尿酸的绝对值上略高一些,而在血胱抑素C及尿微量白蛋白水平上两组存在统计学差异,说明OSAHS患者在一定程度上存在肾脏损害。     

帕金森病人血清胱抑素C水平、尿酸变化与病情分期、认知障碍、运动功能的相关性研究

目的探讨帕金森病(PD)病人血清胱抑素C(CysC)、尿酸(UA)水平变化与病情分期、认知障碍、运动功能的相关性。方法纳入PD病人90例作为PD组,选取同期健康体检者82名作为健康组。比较2组血清CysC与UA水平,根据帕金森Hoehn-Yahr(H-Y)分期将PD病人分成H-Y≥3期组(n=36)、H-Y < 3期组(n=54)。根据蒙特利尔认知评估量表(MoCA)将PD病人分成认知障碍组(n=49,MoCA < 26分)、非认知障碍组(n=41,MoCA≥26分)。根据统一帕金森病评估量表第三部分(UPDRS-Ⅲ)评估PD病人运动障碍程度,并分成轻度组(n=26,0~15分)、中度组(n=41,16~40分)、重度组(n=23,41~56分)。比较不同病情分期、认知障碍、运动功能病人的血清CysC与UA水平,经Pearson线性相关分析血清CysC、UA水平与H-Y分期、MoCA评分、UPDRS-Ⅲ评分的相关性。结果PD组血清CysC高于健康组,但血清UA水平低于健康组(P < 0.01)。H-Y≥3期组血清CysC、H-Y分期较H-Y < 3期组增高,血清UA较H-Y < 3期组降低(P < 0.01)。认知障碍组血清CysC较非认知障碍组增高,血清UA、MoCA评分较非认知障碍组降低(P < 0.01)。重度组血清CysC及UPDRS-Ⅲ评分较中、轻度组增高,且中度组高于轻度组,但重度组血清UA较中、轻度组降低,且中度组低于轻度组(P < 0.01)。Pearson线性相关分析结果显示,PD病人血清CysC与H-Y分期、UPDRS-Ⅲ评分呈正相关,与MoCA评分呈负相关(P < 0.05~P < 0.01),而血清UA与H-Y分期、UPDRS-Ⅲ评分呈负相关,与MoCA评分呈正相关(P < 0.05~P < 0.01)。结论PD病人血清CysC水平增高,而血清UA降低,且二者均与病人的病情分期、认知障碍、运动功能存在相关性,临床可将血清CysC、UA作为评估PD进展的指标。     

帕金森病患者血清半胱氨酸蛋白酶抑制剂C水平的变化及其临床意义

目的 探讨血清半胱氨酸蛋白酶抑制剂C (胱抑素C,Cys-C)水平与帕金森病患者(Parkinson’s disease,PD)的相关性及临床意义。 方法 收集70例PD患者为观察组(PD组),30例健康体检者为对照组,根据Hoehn-Yahr (修正)分级量表(H&Y分期)将PD组分为3个亚组:早期组25例、中期组24例和晚期组21例。应用免疫比浊法检测血清Cys-C水平,比较PD组与对照组血清Cys-C水平的差异及PD组各亚组间血清Cys-C水平的差异;同时分析血清Cys-C与H&Y分期及帕金森病评定量表(UPDRS)运动评分的相关性。 结果 PD组患者血清Cys-C水平明显高于对照组,差异具有统计学意义(t=3.61,P＜0.01);晚期组血清Cys-C水平明显高于中期组及早期组,差异具有统计学意义(P＜0.05,P＜0.01);中期组血清Cys-C水平明显高于早期组及对照组,差异具有统计学意义(P＜0.01,P＜0.01);早期组血清Cys-C水平高于对照组,但差异无统计学意义(t=1.31,P=0.12)。PD组血清Cys-C水平与H&Y分期(r=0.67,P＜0.01)、UPDRS Ⅱ(r=0.64,P＜0.01)及UPDRS Ⅲ(r=0.59,P＜0.01)均呈正相关。 结论 PD患者血清Cys-C水平升高,且血清Cys-C水平与PD的病程进展相关,可反应病情的严重程度,在PD的进展中起一定作用。      

Soluble endoglin和sFlt-1在子痫前期患者血清中的表达

目的探讨可溶性CD105淋巴细胞抗原及可溶性血管内皮生长因子受体1(sFlt-1)在子痫前期患者血清中表达水平的变化及意义。方法采用双抗体夹心酶联免疫吸附(ELISA)法测定子痫前期组、子痫前期各个亚组及正常晚期妊娠组血清sEng及sFlt-1的水平。结果①子痫前期组孕妇血清sEng、sFlt-1水平分别为(5.27±1.05)ng／mL、(391.14±70.25)pg／mL,正常晚期妊娠组分别为(1.26±0.40)ng／mL、(27.57±4.36)pg／mL,两组比较差异有统计学意义(P＜0.01);②轻度子痫前期组sEng水平与重度子痫前期组比较差异有统计学意义(P＜0.01),两组sFlt-1水平比较差异无统计学意义(P＞0.05);③早发型重度子痫前期组sEng水平与晚发型重度子痫前期组比较差异有统计学意义(P＜0.01),两组sFlt-1水平比较差异无统计学意义(P＞0.05)。结论子痫前期患者血清中sEng、sFlt-1水平显著升高,sEng在早发型重度子痫前期血清中升高更显著,对早期诊断子痫前期有重要意义。     

冠心病患者血清sd-LDL和hs-CRP与冠状动脉狭窄程度的相关性研究

目的 比较冠心病患者与健康人群中血清小而密低密度脂蛋白(sd-LDL)、超敏C反应蛋白(hs-CRP)水平的差异,探讨血清sd-LDL、hs-CRP水平与冠状动脉狭窄程度的关系.方法 选取2015年11月至2016年5月期间在武汉大学人民医院住院的冠心病患者542例,其中稳定心绞痛(SA)247例、不稳定性心绞痛(UA)115例、急性心肌梗塞(AMI)180例,同时期同龄来院体检的健康对照者231例,使用全自动生化分析仪检测血清中sd-LDL与hs-CRP的水平,同时根据冠脉造影结果计算冠心病患者Gensini评分,评价冠状动脉的狭窄程度,使用成组t检验分析各组间的差异,使用Spearman's相关性分析法分析sd-LDL、hs-CRP水平与Gensini评分的相关性.结果 与对照组相比,sd-LDL的水平在SA[(1.09±0.55)mmol/L vs(0.71±0.43)mmol/L,P<0.01]、UA[(1.11±0.58)mmol/L vs(0.71±0.43)mmol/L,P<0.01]和AMI组[(1.41±0.61)mmol/L vs(0.71±0.43)mmol/L,P<0.01]中均显著升高;AMI组中sd-LDL的水平较SA组[(1.41±0.61)mmol/L vs(1.09±0.55)mmol/L,P<0.01]和UA[(1.41±0.61)mmol/L vs(1.11±0.58)mmol/L,P<0.01]显著升高.Spearman's相关性分析结果显示,sd-LDL与Gensini积分呈显著正相关(r=0.5202,P<0.01),hs-CRP与Gensini积分呈显著正相关(r=0.2361,P<0.01).结论 小而密低密度脂蛋白是冠心病的危险因素,与冠心病的临床分型和冠状动脉的狭窄程度密切相关.sd-LDL与hs-CRP联合检测对冠心病的风险预测及严重程度的判断均有重要的临床意义.     

Brain natriuretic peptide and copeptin levels are associated with cardiovascular disease in patients with chronic kidney disease

Background Cardiovascular disease (CVD) is the leading cause of death in patients with end-stage renal disease (ESRD).We explored the relationship between CVD,plasma brain natriuretic peptide (BNP) and...     

血清胱抑素C评估肾功能在糖尿病病人中的临床应用价值

目的:评价血清胱抑素C(Cys-C)水平对于糖尿病病人肾功能不全的临床检测意义.方法:选取225例糖尿病病人,记录性别、年龄、病程、血压、身高及体质量,计算出体质量指数(BMI),使用肾动态显像法测定肾小球滤过率(GFR)(mL·min-1·1.73 m-2)值.所有病人分为3组:A组(GFR<60)、B组(60≤GFR<90)、C组(GFR≥90).检测血清胱抑素C(Cys-C)、血清视黄醇结合蛋白(RBP)、血肌酐(Scr)、血尿素(Sur)、血尿酸(UA)、24 h尿微量白蛋白(UmAlb).结果:3组病人年龄、病程、Scr、Sur、UA、RBP、Cys-C和UmAlb差异均有统计学意义(P<0.05);3组病人年龄、病程、Scr、Sur、UA、RBP、Cys-C、UmAlb与GFR均呈负相关关系(P<0.01);多元逐步回归显示Cys-C、年龄、UmAlb进入最佳方程,且血清Cys-C最先进入.结论:Cys-C、年龄、UmAlb是影响糖尿病病人GFR的主要因素,其中血清Cys-C是反映早期肾功能受损的一个更为理想、敏感的常规指标,有助于糖尿病肾脏疾病的早期防治.     

急性心肌梗死、脑梗死与血尿酸关系分析

目的: 探讨急性心肌梗死(AMI)、脑梗死(CI)的发病与血尿酸(UA)的关系。方法: 检测36例急性心肌梗死患者、48例脑梗死患者血尿酸水平,并与40名正常对照组进行统计学分析。结果: 急性心肌梗死组血尿酸值男性(428.76±22.10)μmol/L,女性(380.21±18.35)μmol/L,明显高于正常对照组(P<0.01)。脑梗死组血尿酸值男性(396.91±17.30)μmol/L,女性(323.46±16.34)μmol/L,亦明显高于正常对照组(P<0.01)。且AMI、CI两组间差异亦有显著性(P<0.01)。结论: 血尿酸增高可能是急性心肌梗死和脑梗死危险因素之一。     

血清尿酸水平与帕金森病不同运动亚型之间的关系

目的:探讨血清尿酸(UA)水平与帕金森病(PD)不同运动亚型及临床分期之间的关系.方法:入选PD病人(PD组)及年龄、性别相匹配的健康对照组(HC组)各50例,PD病人根据运动障碍症状分为震颤为主型(TD组)和姿势异常及步态障碍为主型(PIGD组);病情严重程度采用Hoehn-Yahr(H-Y)分级评定为早期(H-Y<3级)及中晚期(H-Y≥3级).分别测定各组血清UA水平,同时检测血清肌酐(Cr)水平.结果:PD组血清UA水平低于HC组(P<0.01);PIGD组血清UA水平较TD组明显降低(P<0.05);中晚期PD病人血清UA水平低于早期(P<0.01).各组血清Cr水平差异无统计学意义(P>0.05).结论:UA水平的变化可能参与了PD不同运动亚型的发病机制,并可能成为预测PD发病风险、判断病情严重程度及运动分型的生物学标志物.